Journal of ISSN: 2373-4310JNHFE

Nutritional Health & Food Engineering
Mini Review
Volume 6 Issue 2 - 2017
Gut Microbiota, a Key Factor Relating Diet and Inflammation with the Progression of Cognitive Impairment in Older People
Gaspar Perez Martinez*
Departamento de Biotecnología, Instituto de Agroquimíca y Tecnología de Alimentos (C.S.I.C.), Valencia, Spain
Received: October 01, 2016 | Published: February 15, 2017
*Corresponding author: Gaspar Pérez Martínez, Departamento de Biotecnología, Instituto de Agroquimíca y Tecnología de Alimentos (C.S.I.C.), Avenida Catedrático Agustín Escardino, 7, 46980 - Paterna, Valencia, Spain, Tel: +34 96 3900022 (Ext. 2021), Fax: + 34 96 3636301; Email:
Citation: Martinez GP (2017) Gut Microbiota, a Key Factor Relating Diet and Inflammation with the Progression of Cognitive Impairment in Older People. J Nutr Health Food Eng 6(2): 00192. DOI: 10.15406/jnhfe.2017.06.00192


Developed societies are facing a remarkable increase of population’s longevity and, consequently, of chronic diseases such as obesity, cardiovascular or neurodegenerative diseases. Age associated cognitive impairment (CI) (dementia) in its different forms represent a real social, economic and public health problem, and particularly the severe and highly prevalent Alzheimer disease (AD). Inflammation and altered metabolism of neurotransmitters and hormones are common in elderly suffering CI and AD. Metagenomics studies have demonstrated that in normal adult population, as well as in older people, health status and diet are the main factors affecting microbiota composition. Older persons frequently develop immune system degeneration leading to a low response to antigens and to a low profile persistent inflammation (inflammaging). Data from elderly populations and disease models show that systemic inflammation alters gut microbiota and also certain changes in the microbiota induce inflammatory secretions. In addition, there is a more than likely role of gut microbiota in the gut-brain signalling through the synthesis and processing of neurotransmitters. Hence, changes occurring in the gut microbiota of the elderly mostly due to diet, environment and inflammatory processes might be associated to brain function. The objective of this review would be to show that there are evidences that link gut microbiota and cognitive decline through inflammatory processes, although direct action on neurotransmitters may not be discarded. Research data shown here supports the view that inflammation linked to neurodegenerative diseases associated to ageing, may cause changes in the gut microbiota composition that, turn, would feed inflammation and aggravating the disease. This perverse cycle has been delayed to a certain extent through a healthy diet rich in complex carbohydrates, such as the Mediterranean diet.

Keywords: Gut Microbiota; Ageing, Diet; Inflammation; Cognitive Impairmen


5-HT: 5 Hydroxy Triptamine; AD: Alzheimer Disease; Aβ: Amyloid-β; Aβ 1-42 and Aβ 1-40: Shorter peptides of Aβ released during pathogenesis; ApoE: Apolipoprotein E; CI: Cognitive Impairment; CMV: Cytomegalovirus; CRP: C Reactive Protein; CSF: Cerebrospinal Fluid; CSN: Central Nervous System; DA: Dopamine; EBV Epstein-Barr Virus; GF: Germ Free; IBS: Irritable Bowel Byndrome; IL-6; Inter Leukin 6; IL-8: Inter Leukin8; MAMPS: Microbe Associated Molecular Patter NA: NorAdrenalin PET: Positron Emission Tomography; PPA: Precursor Protein Amyloi; p-tau: Phosphorylated Tau Protein; SCFA: Short Chain Fatty Acid; sLRP : Soluble Low Density Lipoprotein Receptor-Related Protein-1; SPF: Specific Pathogen Free; sRAGE: Soluble Receptor for Advanced Glycation End Products; TNF-α: Tumor Necrosis factor Alpha


The aim of this first part is providing solid grounds to propose links between gut microbiota and cognitive decline through inflammatory processes, although direct action on neurotransmitters may also have an incidence. Hence, it will be needed to update the state of the art on CI and AD, and their links with inflammatory processes will be revealed through the study of molecular markers. Finally, the relationship of gut microbiota with brain function and changes during ageing will be reviewed.

Cognitive impairment and alzheimer disease

Life expectancy has greatly improved in the last century, generating unprecedented social and public health problems, due to the great increase of the older population. In fact, different forecasts suggest that 50% of today’s young people will reach 90 years and, if present proportions persist, between 40-60% of them will suffer some sort of cognitive impairment or AD after that age (90 years). Hence, if we are unable to find a solution, in two to three decades there will be more dements than ever before in human history [1,2]. Unfortunately, all studies revealed that age is the main risk factor for CI or AD and it duplicates every 10 years, therefore, our “oldest old” - that is older than 90 years- are those at greater risk. Different works have tried to determine other risk factors and although a significant correlation has been found between longevity and the intake of vitamins, antioxidants, physical activity, caffeine, alcohol or body mass index, it was not possible to find any relationship with the development of neurodegenerative diseases. Among all factors studied that may influence the development of CI or AD, only hypertension has been clearly determined to reduce and hypotension to increase the risk to develop dementia. The causes are yet undetermined, but it has been suggested that brain capillaries develop rigid walls with age and contorted paths require greater tension for the adequate perfusion of nutrients and oxygen [3-5]. The presence of amyloid-β (Aβ) protein is a definite risk factor, as 60% of old persons with dementia show presence of Aβ after positron emission tomography (PET) scan, and 40% of healthy volunteers of similar age (>90) showed the presence of Aβ. However, this healthy group positive for Aβ lost their cognitive faculties faster than the healthy group with no Aβ signal [6]. Aβ plates have an important role in AD pathogenesis, but the severity of the cognitive impairment holds greater correlation with the burden of neocortical neurofibrillary tangles than with the presence of Aβ plates [7]. In elderly of very advanced age (more than 90-95 years), the pathology of AD depends rather on genetic factors than on age itself due to the appearance of the precursor protein amyloid-β (PPA).Nowadays, different causes of dementia can be histological differentiated among them, of course, AD and hippocampus sclerosis. The main neuropath logical features of AD are the loss of neurons and synopsis, the formation of plates (of Aβ protein) and neurofibrillary tangles (aggregates of tau protein associated to microtubules) in the cortical and limbic regions of the brain, and until present, the most efficient diagnostic of AD is obtained through lumbar puncture for the detection of Aβ 1-42 and Aβ 1-40, total tau protein or phosphorylated tau (p-tau) [8,9]. CI and AD can be classified as diseases of inflammatory nature due to the high concentrations of inflammatory markers detected (see below); prolonged anti-inflammatory treatments reduce the risk of their development. Although the causal relationship between inflammation and CI or AD has not been disclosed, but some molecular components of inflammatory events promote pathological processes that lead to AD, while others have the opposite effect. This apparently depends on the way they affect different types of cells in the brain of different individuals [10].

Investigation and diagnostic of cognitive impairment and alzheimer disease through molecular methods

The clinical diagnostic of AD is mainly based on neuro-psychological symptoms and until recently this disease required the post mortem confirmation of the presence of Aβ plates and fibrillary tangles in the cortex for 100% precise diagnostic [11]. Therefore, in the last years a great effort has been devoted to determine molecular markers for robust, and if possible, early diagnostics of AD. The protein analysis of cerebrospinal fluid (CSF) (βA 1-42 (INNOTEST®), ApoE, tau and phosphorylated tau is now considered the most precise method for the diagnostic of AD [12-15]. Attempts to develop less invasive methods were published based on the detection of multiple plasma molecular markers (between 18 and 89) that showed a precision of 70% for early detection of CI and AD [16,17]. Later studies developed methods for the analysis of individual markers in plasma, such as the presence of the soluble form of the receptor for advanced glycation end products (sRAGE) and the soluble low density lipoprotein receptor-related protein-1 (sLRP) [18]. Metabolites of different fluids have been characterized through metabolomics in AD transgenic mouse models and humans with AD and CI. In general terms, detected products in plasma and CSF followed parallel patterns and likely differences were found between normal elderly people and those affected by AD or CI (up to 40-60% of total compounds). Differential patterns were mainly found in canonical pathways related to the energy metabolism and mitochondrial function, lipid biosynthesis and transport, and metabolism of neurotransmitters and hormones. Remarkably, some of these signatures and profiles can be explained by the metabolism of the gut microbiota, as will be reviewed below [19-23]. The detection of individual compounds can be used as a fast diagnostic method. For example, the presence of cortisol in saliva could be shown in a number of works that holds direct relationship with stress [24], determined through ELISA techniques [25]. However, cortisol determination can also be related to neurodegenerative processes, especially CI and AD, as marker of the hypothalamus and the adrenocortical gland activity [26] and it can be determined as a typical CSF metabolite in AD [27]. Since 2005 gene expression studies (transcriptomics) tried to discriminate differences between healthy volunteers and CI and AD patients using DNA microarrays on nervous tissue and CSF samples [28]. The amount of information obtained was precise and abundant, but those studies underestimated posttranscriptional events, offering only a partial view of such biological problems. On the other hand, the transcriptomic analysis of blood cells may offer a more general view on the status of the organism. A very complete blood study by [29] described differential expression of more than 2,900 probes between controls and patients with CI and AD. The most significant group (77) had lower level of expression in the subjects affected by CI and AD, from which authors underpinned genes mainly related to the respiratory chain of mitochondria. Of note, the only group of genes significantly over expressed in the disease cases were related with inflammatory immune response, particularly pathways related to endothelial leukocyte migration, oxidative phosphorylation and ribosomal synthesis [29].

Finally, newly developed imaging techniques need to be mentioned. PET and magnetic resonance imaging (MRI) are non-invasive methods with great in vivo resolution that have successfully been applied to humans. PET with 2-[18F] fluoro-2-deoxy-D-glucose (FDG) has been globally used for more than 20 years. This probe detects general levels of metabolic activity, and images obtained have enough resolution for some expert professionals to determine if patients are suffering CI or AD [30]. In the past years, radiolabelled probes applied are able to directly detect Aβ with great efficacy, for example, results using [11C]-Pittsburg compound-B (PIB) rendered a robust diagnostic of the fibrillary deposition of the amyloid protein in the neocortex on 238 volunteers of a multicenter study [31]. Also the ratio of Aβ 1-42/ Aβ 1-40 using high precision mass spectroscopy were definitely associated with the presence of cortical Aβ fibrils [32].

Gut microbiota and the gut-brain axis

Humans have coevolved during millions of years with a variety of microbial species in such a way that we need a balanced gut microflora (microbiota) for food digestion, pathogen inhibition, preservation of the gut mucosa integrity, so that from the moment of birth, we depend on the gut microbiota to achieve a proper maturation of the immune system [33,34]. Changes in the composition of the microbiota exert an effect on the host physiology, contributing to the development of diseases that involve inflammatory disorders, type II diabetes, obesity, metabolic syndrome (for reviews see [35-38] and liver functions [39]. The axis Brain-Intestine has long been known to affect intestinal functions under stress or anxiety conditions (up-down signal). Here we will focus on the “down-up” signal and will show some experimental examples that highlight such Gut-Brain communication mechanism. The fact that gut microbiota can transcend the digestive and immune functions is still confronted by the skepticism of some clinicians, but there are sound scientific evidences of the existence of signaling pathways between gut microbiota and the brain. Four transport paths have been proposed for signals from Gut (microbiota) to Brain: the vagus nerve and spinal efferent systems; mediators of the immune system, such as cytokines; enteric hormones; and finally, signaling molecules produced by the gut microbiota [40]. Some examples are following that will shed light on these mechanisms. It has been shown that germ free (GF) mice displayed greater motor activity and less anxiety than mice colonized with normal microbiota (SPF). This difference can be attributed to an increase in noradrenalin (NA), dopamine (DA) and 5-hydroxytriptamine (5-HT) turnover in the striatum of GF mice, known monoamine neurotransmitters associated to anxiety-like behavior, and to changes in expression of genes that participate in the synaptic plasticity [39]. In a different study, GF male mice showed a significant increase in hippocampus concentration of 5-HT (serotonin), if compared to conventionally colonized animals. In fact, the concentration of tryptophan, precursor of serotonin, was higher in plasma of GF mice, suggesting that gut microbiota may influence serotonergic neurotransmission of the central nervous system (CNS) via humoral communication path [41]. Different works could demonstrate that the vagus nerve serves as an important neurotransmitter of the changes occurring in the gut microbiota. These studies described assays in which the intake of probiotc strains, Lactobacillus rhamnosus and Bifidobacterium longum, did not reduce inflammatory markers, however, they managed to normalize the anxiety related behavior caused by colitis, a process mediated by the vagus nerve that is possibly activated at the level of the enteric nervous system [42]. Particularly, L. rhamnosus (JB-1) induced gene expression changes of the receptor of γ-aminobutiric acid (GABA) in different regions of the brain, as well as a reduction of the levels of corticosterone and the anxiety/depression related behavior. Those behavioral and neurochemical effects were not present in vagotomized mice [43]. Catecholamines (CA) can also be involved in the Gut-Brain signaling regulated by gut bacteria. Much lower levels of dopamine and norepinephrine have been found in the intestinal lumen of GF mice than in conventional SFP mice, further, CA found in SPF mice were biologically active, while those in GF mice were conjugated or inactive [44]. Manipulation of the microbiota in rodents gives rise to changes in the regulation of anxiety, mood, cognition and pain, that led to suggest that proper modification of the gut microbiota could be an optional strategy in the development of new therapies in complex CNS disorders [45]. In this line, some studies related changes in the gut microbiota with autism, anxiety and depression also in humans, however, the signaling channels are still under research [46]. It could be demonstrated that chronic intestinal infection in animal models is related to an anxiety and depression related behavior, effects that are associated to changes in the patterns of proinflammatory cytokines and metabolic pathways of kinurenine/tryptophan [47]. In humans, the irritable bowel syndrome (IBS) is correlated to intestinal inflammation and a strong deviation of the normal gut microbial pattern (dysbiosis). Since gut inflammation is the basis of systemic inflammation, endotoxemia and neuroinflammation, this would explain why a high proportion of IBS patients (also consuming alcohol, tobacco and high fat diets), have a high risk to suffer respiratory, neuromuscular, psychological, sleep or neurological disorders, stressing the effect of the communication paths between dysbiosis, gut and the CNS [48]. In a mouse model of the ME7 prion disease, systemic inflammation induced acute cognitive deficiencies [49]. Regarding the incidence of the general inflammatory condition on dementia in humans, a recent meta-analysis demonstrated that high levels of peripheral inflammatory markers are related to a slight increase in the risk of dementia in the broad sense, not to AD [50].

Microbiota and the immune system in the elderly

Ageing brings along deregulation of the immune response due to a life-long hyper stimulation of the immune system (immunosenescence). At advanced age, there is a lower response to antigens due to thyme involution, with a reduction of total T and B cells, and naïve T cells (CD95-) needed for the production of new immunoglobulins (Ig) against pathogens. As consequence of age, there is also an accumulation of effector T cells (CD8+) that produce pro-inflammatory cytokines, an increase of Natural Killer (NK) cells and a progressive activation of macrophages, all this is displayed with constant low grade inflammatory signaling (inflammaging). This inflammatory stage in elderly people has been related to different age related diseases, from diabetes to cardiovascular or neurodegenerative diseases (for review see [51]. Certain viral infections, such as Epstein-Barr Virus (EBV) and cytomegalovirus (CMV) [52]. Significantly participate in the development of the chronic pro-inflammatory state in elderly. This inflammatory scenario sensitizes elderly to microbe associated molecular patterns (MAMPS) that originate an inflammatory loop that may explain why changes in microbiota composition are related with the progression of diseases and frailty in older population, although at present we cannot explain what occurs first [53]. Thus, the maintenance of a stable and “healthy” microbiota could prevent or delay the inflammatory state associated to age (inflammaging). Certain bacterial groups, such as Faecal bacterium, lactobacilli and bifidobacteria can modulate the pro-inflammatory response [54-57]. In fact, the presence of strains of the genus Bifidobacterium in the gut microbiota of elderly is negatively correlated with high levels of the pro-inflammatory cytokine TNF-α and with the interleukine 10 (IL-10) [58]. On the other hand, the increase of Enterobacteriaceae and other Proteobacteria is related to the reduction of short chain fatty acids (SCFA) in feces, lower secretion of mucins, a greater stimulation of bacterial endotoxins, as well as the reduced permeability of the intestinal barrier, favoring the severity of the immune response and reducing the tolerance to otherwise harmless commensal bacteria, which under those conditions are turned into a strong pro-inflammatory stimulus [59,60]. Microbiota changes with age and it was proposed that older people have a higher proportion of Bacteroidetes vs. Firmicutes, and low presence of bifidobacteria [61]. However, recent studies could not find significant differences between microbiota in healthy adults and elderly of more than 65 years. Nevertheless in older persons, there is a clear relationship between the health status, diet and age related decline, particularly parameters of frailty, co-morbidity, nutritional status, inflammatory markers and fecal water metabolites. Inflammatory markers (TNF-α, IL-6, IL-8 and the C reactive protein (CRP)) had higher levels in institutionalized subjects than in community dwelling elderly [62]. This relationship between the immune system, microbiota and age becomes relevant in AD patients. The immune system of old persons susceptible to AD could be weaker, as deduced from the significant relationship between the evolution towards mild cognitive impairment and AD and the presence of antibodies against bacteria typically associated to periodontal infections, such as Fusarium nucleatum and Prevotella intermediate [63].


During the last years, human studies on the composition of the gut microbiota have generated massive amounts of data in different individuals and conditions. One of the main observations was that significant relationships could be established between “core” bacterial populations in the gut associated to different diets. Initially, three enterotypes were described after the dominant bacterial groups, they were the Bactericides enterotype, associated to diets rich in protein, simple sugars and animal fat and, Prevotella and Ruminococcus enterotypes related to high fiber intake [64]. Subsequent publications simplified this classification to Bacteroides and Prevotella enterotypes [65]. The Prevotella enterotype was not only bound to complex carbohydrate consumption but resulted in a more efficient utilization of fiber and release of beneficial SCFAs in individuals carrying this enterotype [66]. Similar conclusion was drawn by a study (cited above) that constitutes a landmark of the gut microbiota research in elderly [62]. These authors analyzed microbiota of 178 volunteers ≥65 years old and obtained the covariance with other factors, like community dwelling vs. long stay in institutions, clinical indicators of frailty, inflammation and dietary profiles. This study clearly determined that a long stay in institutions was bound to different bacterial groups and to inflammatory markers (TNF-α, IL-6 and IL-8 and CRP), but also found that individuals in institutions followed a diet richer in animal fat and with less fiber. These volunteers had a less diverse microbiota, a lower functional independence, depression, and mini-mental cognitive test scores. A gradient was observed as individuals changed from community dwelling to long stay in institutions, following a decrease of SCFAs in feces and bacteria from the genera Prevotella and Ruminococcus. This work suggested a clear connection between gut microbiota/diet and mental status in older persons. The Mediterranean diet has a direct impact on the gut microbiota can be established through its high content in vegetables and complex carbohydrates that favor the proliferation of Prevotella [67]. Furthermore, recent meta-analysis reported that a better adherence to Mediterranean diet can delay cognitive decline [68]. And even ApoE ε4 allele carriers had a better performance in executive function after 36 months [69]. Both studies suggesting a fundamental role of the gut microbiota. But how are intestinal bacteria connected to brain function? Different studies mentioned above showed that changes in the gut microbiota lead to altered expression of anxiety and synaptic plasticity genes [39]. And changes in the behavior (anxiety and social interaction) of mice [70]. However, due to intrinsic difficulties of the mouse models, a clear connection could not be established with cognitive faculties but, in humans, depression in inflammatory diseases, like IBS, have been related to cognitive decline [48]. Then, inflammation can be the link. AD is considered disease where inflammation does not exclusively affect the CNS, it also implies systemic dysfunction of metabolic, inflammatory, and biochemical pathways. Certainly, inflammaging was described as a low-grade, controlled, asymptomatic, chronic, systemic, inflammatory state, affecting older people has been related to many age related diseases [71]. And particularly to frailty and faster cognitive decline in the elderly [72-74].


This is a multidisciplinary topic that is developing very fast in the last few years, as ageing health complications and the need for empowerment of older citizens constitute institutional priorities in modern society. Other comprehensive reviews have tried to condense the numerous interacting factors and very complex causalities of cognitive impairment including frailty, depression, inflammation or oxidative stress, among others [73]. This review has a different aim, to summarize scientific reports in a simple scheme that could connect four main factors: age, gut microbiota, diet and inflammation with cognitive decline (Figure 1). Age prompted inflammaging, results in a chronic, systemic inflammation that has a direct impact on the composition of the gut microbiota, but also causes the general health decline, including frailty, depression and accelerates AD and dementia. Diet and possible dietary interventions (probiotics and prebiotics) may help to manage deviations of the gut microbiota. Particularly, the Mediterranean diet has a positive impact on the microbiota, increasing the populations of Prevotella and the production of beneficial SCFAs by gut bacteria. Although out of this context, this diet also provides Omega 3 and Omega 6 fatty acids that improve cardiovascular disease, a health problem with a known negative impact on cognitive performance.

Figure 1: Scheme representing demonstrated (black arrows) and modelled relationships (grey arrow) occurring during ageing between Gut Microbiota, Diet, Mood and Depression, Inflammation and Cognitive Faculties, where inflammatory processes play a central role. This is described in detail in the Discussion and Conclusions.


Author wishes to thank Spanish Ministerio de Economia y Competitividad projects AGL2013-47420-R and AGL2015-70487-P for the financial support.


  1. Bullain SS, Corrada MM (2013) Dementia in the oldest old. Continuum (Minneap Minn) 19(2): 457-469.
  2. Christensen K, Doblhammer G, Rau R, Vaupel JW (2009) Ageing populations: the challenges ahead. The Lancet 374(9696): 1196-1208.
  3. Morris MC, Scherr PA, Hebert LE, Glynn RJ, Bennett DA (2001) Association of incident alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Archives of Neurology 58(10): 1640-1646 .
  4. Nilsson SE, Read S, Berg S, Johansson B, Melander A, et al. (2007) Low systolic blood pressure is associated with impaired cognitive function in the oldest old: longitudinal observations in a population-based sample 80 years and older. Aging Clin Exp Res 19(1): 41-47.
  5. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ et al. (2005) Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57(6): 789-794.
  6. Kawas CH, Greenia DE, Bullain SS, Clark CM, Pontecorvo MJ et al. (2013) Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study. Alzheimer's & dementia : the journal of the Alzheimer's Association 9(2): 199-203.
  7. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71(5): 362-381.
  8. Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L (2013) Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. Journal of Neurology 260(2): 620-626.
  9. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, et al. (2011) Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 134(5): 1506-1518.
  10. Wyss-Coray T, Rogers J (2012). Inflammation in Alzheimer Disease-A Brief Review of the Basic Science and Clinical Literature. Cold Spring Harbor Perspectives in Medicine 2(10: a006346.
  11. Sabbagh MN, Cooper K, DeLange J, Stoehr JD, Thind K, et al. (2010) Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res 7(4): 280-286.
  12. Blennow K, Zetterberg H (2013) The Application of Cerebrospinal Fluid Biomarkers in Early Diagnosis of Alzheimer Disease. Medical Clinics of North America 97(3): 369-376.
  13. Monge Argiles A, Blanco Canto MA, Leiva Salinas C, Flors L, Munoz Ruiz C et al. (2013) A comparison of early diagnostic utility of Alzheimer disease biomarkers in brain brain magnetic resonance and cerebrospinal fluid. Neurologia 29(70): 397-401.
  14. Rosen C. Zetterberg, H (2013) Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease. Curr Opin Psychiatry 26(3): 276-282.
  15. Wang C, Yu JT, Wang HF, Jiang T, Tan CC, et al. (2014) Meta-Analysis of Peripheral Blood Apolipoprotein E Levels in Alzheimer’s Disease. PLoS ONE 9(2): e89041.
  16. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, et al. (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362.
  17. Soares HD, Chen Y, Sabbagh M, Roher A, Schrijvers E, et al. (2009) Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels. Annals of the New York Academy of Sciences 1180: 56-67.
  18. Liang F, Jia J, Wang S, Qin W, Liu G (2013) Decreased plasma levels of soluble low density lipoprotein receptor-related protein-1 (sLRP) and the soluble form of the receptor for advanced glycation end products (sRAGE) in the clinical diagnosis of Alzheimer’s disease. Journal of Clinical Neuroscience 20(3): 357-361.
  19. Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C (2009) A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease Electrophoresis 30(7): 1235-1239.
  20. Motsinger-Reif A, Zhu H, Kling M, Matson W, Sharma S, et al. (2013) Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun 1: 28.
  21. Orešič M, Hyötyläinen T, Herukka SK, Sysi-Aho M, Mattila I, et al. (2011) Metabolome in progression to Alzheimer's disease. Transl Psychiatry 1: e57.
  22. Trushina E, Mielke MM (2013) Recent advances in the application of metabolomics to Alzheimer's Disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1842(8): 1232-1239.
  23. Zhu H, Luo M (2014) Chemical structure informing statistical hypothesis testing in metabolomics. Bioinformatics 30(4): 514-522.
  24. Hellhammer DH, Wüst S, Kudielka BM (2009) Salivary cortisol as a biomarker in stress research. Psychoneuroendocrinology 34(2): 163-171.
  25. Inder WJ, Dimeski G, Russell A (2012) Measurement of salivary cortisol in 2012 - laboratory techniques and clinical indications. Clin Endocrinol (Oxf) 77(5): 645-651.
  26. Meyer JS, Novak MA (2012) Minireview: Hair Cortisol: A Novel Biomarker of Hypothalamic-Pituitary-Adrenocortical Activity. Endocrinology 153(9): 4120-4127.
  27. Czech C, Berndt P, Busch K, Schmitz O, Wiemer J (2012) Metabolite Profiling of Alzheimer's Disease Cerebrospinal Fluid. PLoS One. 7(2): e31501.
  28. Ho L, Sharma N, Blackman L, Festa E, Reddy G (2005) From proteomics to biomarker discovery in Alzheimer's disease. Brain Research Reviews 48(2): 360-369.
  29. Lunnon K, Ibrahim Z, Proitsi P, Lourdusamy A, Newhouse S, et al. (2012). Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. Journal of Alzheimer's Disease 3093): 685-710.
  30. Mosconi L, Berti V, Glodzik L, Pupi A, De Santi S, et al. (2010) Pre-Clinical Detection of Alzheimer's Disease Using FDG-PET, with or without Amyloid Imaging. Journal of Alzheimer's Disease 20(3): 843-854.
  31. Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, et al. (2013) A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease. European Journal of Nuclear Medicine and Molecular Imaging 40(1): 104-114.
  32. Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, et al. (2016) Reference measurement procedure for CSF Aβ1-42 and the CSF Aβ1-42/Aβ1-40 ratio - a cross-validation study against Amyloid PET. J Neurochem 139(4): 651-658.
  33. Collado MC, Cernada M, Baüerl C, Vento M, Pérez-Martínez G (2012) Microbial ecology and host-microbiota interactions during early life stages. Gut Microbes 3(4): 352-365.
  34. Zeissig S, Blumberg RS (2014) Life at the beginning: perturbation of the microbiota by antibiotics in early life and its role in health and disease. Nat Immunol 15(4): 307-310.
  35. Blaut M, Klaus S (2012) Intestinal microbiota and obesity. Handb Exp Pharmacol (209): 251-273.
  36. Gruber L, Lichti P, Rath E, Haller D (2012) Nutrigenomics and nutrigenetics in inflammatory bowel diseases. J Clin Gastroenterol 46(9): 735-747.
  37. Kelly D, Mulder IE (2012) Microbiome and immunological interactions. Nutr Rev 70 (Suppl 1): 1753-4887.
  38. Tremaroli V, Bäckhed F (2012) Functional interactions between the gut microbiota and host metabolism. Nature 489(7415): 242-249.
  39. Diaz Heijtz R, Wang S, Anuar F, Qian Y, Björkholm B (2011) Normal gut microbiota modulates brain development and behavior. Proceedings of the National Academy of Sciences 108(7): 3047-3052.
  40. Holzer P, Farzi A (2014) Neuropeptides and the Microbiota-Gut-Brain Axis. Adv Exp Med Biol 817: 195-219.
  41. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD (2013) The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry 18(6): 666-673.
  42. Bercik P, Park AJ, Sinclair D, Khoshdel A, Lu J (2011) The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communication. Neurogastroenterology & Motility 23(12): 1132-1139.
  43. Bravo JA, ForsytheP, Chew MV, Escaravage E, Savignac HM, et al. (2011) Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proceedings of the National Academy of Sciences 108(38): 16050-16055.
  44. Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, et al. (2012) Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol 303(1): 1288-1295.
  45. Cryan JF, Dinan TG (2012) Mind altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13(10): 701-712.
  46. Mayer EA (2011) Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 12(8): 453-466.
  47. Bercik P, Collins SM (2014) The effects of inflammation, infection and antibiotics on the microbiota-gut-brain axis. Adv Exp Med Biol 817: 279-289.
  48. Daulatzai M (2014) Chronic Functional Bowel Syndrome Enhances Gut-Brain Axis Dysfunction, Neuroinflammation, Cognitive Impairment, and Vulnerability to Dementia. Neurochem Res 39(4): 624-644.
  49. Murray C, Sanderson DJ, Barkus C, Deacon RM, Rawlins JN (2012) Systemic inflammation induces acute working memory deficits in the primed brain: relevance for delirium. Neurobiology of Aging 33(3): 603-616.
  50. Koyama A, O'Brien J, Weuve J, Blacker D, Metti AL (2013) The Role of Peripheral Inflammatory Markers in Dementia and Alzheimer’s Disease: A Meta-Analysis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 68(4): 433-440.
  51. Pérez Martínez G, Bäuerl C, Collado MC (2014) Understanding gut microbiota in elderly's health will enable intervention through probiotics. Beneficial Microbes 5(3): 235-246.
  52. Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, et al. (2008) The immune system in extreme longevity. Experimental Gerontology 43(2): 61-65.
  53. Guigoz Y, Doré J, Schiffrin EJ (2008) The inflammatory status of old age can be nurtured from the intestinal environment. Current Opinion on Clinical Nutrition and Metabolic Care 11(1): 13-20.
  54. Bäuerl C, Llopis M, Antolín M, Monedero V, Mata M, et al. (2013) Lactobacillus paracasei and Lactobacillus plantarum strains downregulate proinflammatory genes in an ex vivo system of cultured human colonic mucosa. Genes Nutr 8(2): 165-180.
  55. Heuvelin E, Lebreton C, Grangette C, Pot B, Cerf-Bensussan N (2009) Mechanisms Involved in Alleviation of Intestinal Inflammation by Bifidobacterium Breve Soluble Factors. PLoS ONE 4(4): e5184.
  56. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez-Humarán LG, et al. (2008) Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences 105(43): 16731-16736
  57. Van Baarlen P, Troost F, van der Meer C, Hooiveld G, Boekschoten M, et al. (2010) Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. PNAS 108(Suppl 1): 4562-4569
  58. Ouwehand AC, Bergsma N, Parhiala R, Lahtinen S, Gueimonde M, et al. (2008) Bifidobacterium microbiota and parameters of immune function in elderly subjects. FEMS Immunology and Medical Microbiology 53(1): 18-25.
  59. Biagi E, Nylund L, Candela M, Ostan R, Bucci L (2010) Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians. PLoS One 5(5): e10667.
  60. Schiffrin EJ, Morley JE, Donnet-Hughes A, Guigoz Y (2010) The inflammatory status of the elderly: The intestinal contribution. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 690(1-2): 50-56.
  61. Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, et al. (2009) The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiology 9: 123.
  62. Claesson MJ, Jeffery I B, Conde S, Power SE, Eibhlís MO, et al. (2012) Gut microbiota composition correlates with diet and health in the elderly. Nature 488(7410): 178-184.
  63. Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, et al. (2012) Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimer's & Dementia 8(3): 196-203.
  64. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, et al. (2011) Enterotypes of the human gut microbiome. Nature 473(7346): 174-180.
  65. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, et al. (2011) Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes. Science 334(6052): 105-108.
  66. Chen T, Long W, Zhang, C, Liu S, Zhao L, et al. (2016) Fiber utilizing capacity varies with Prevotella versus Bacteroides enterotypes. The FASEB Journal 30(2): 683-682.
  67. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, et al. (2015) High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut: 1-2.
  68. Van de Rest O, Berendsen A A, Haveman-Nies A, de Groot LC (2015) Dietary Patterns, Cognitive Decline, and Dementia: A Systematic Review. Adv Nutr 6(2): 154-168.
  69. Gardener SL, Rainey-Smith SR, Barnes MB, Sohrabi HR, Weinborn M, et al. (2015) Dietary patterns and cognitive decline in an Australian study of ageing. Mol Psychiatry 20(7): 860-866.
  70. Dinan TG, Stilling RM, Stanton C, Cryan JF (2015) Collective unconscious: How gut microbes shape human behavior. Journal of Psychiatric Research 63: 1-9.
  71. Franceschi C, Campisi J (2014) Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 69(Suppl 1): S4-S9.
  72. Forlenza OV, Diniz BS, Talib LL, Mendonça VA, Ojopi EB (2009) Increased Serum IL-1β Level in Alzheimer’s Disease and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders 28(6): 507-512.
  73. Robertson DA, Savva GM, Kenny RA (2013) Frailty and cognitive impairment-A review of the evidence and causal mechanisms. Ageing Research Reviews 12(4): 840-851.
  74. Trollor JN, Smith E, Agars E, Kuan SA, Baune BT, et al. (2012) The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study. Age 34(5): 1295-1308.
Scholar Awards

At MedCrave we believe that knowledge should be shared. We also believe that   Read more...

Paper of the Year

In regard to the novelty and excellence of the manuscript MedCrave Group (MCG)   Read more...

Financial Support

MedCrave loves to recognize all the outstanding services delivered in the realms   Read more...


MedCrave accelerates the advancement of scientific research by convening   Read more...

MedCrave Reprints

MedCrave Group is ardent to provide article reprints at an instant affordable Read more...

© 2014-2017 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy